Connect with us

Hi, what are you looking for?

Jewish Business News

Business

US court dismisses Teva suit to block generic Copaxone

Published

–

Mylan CEO Heather Bresch: Teva’s suit against the FDA was simply a desperate, last minute tactic.

 –

Copaxone

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
–
“We continue to see no barrier to FDA approval of Mylan’s generic Copaxone following patent expiry, and we look forward to being able to launch this very important first generic product for multiple sclerosis at market formation, ” said Mylan Inc. (Nasdaq: MYL) CEO Heather Bresch, after the US District Court for the District of Columbia ruled against Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; TASE: TEVA) in its lawsuit against the US Food and Drug Administration (FDA) for lack of jurisdiction. Teva had filed a motion to block FDA from approving generic versions of Copaxone, its brand treatment for multiple sclerosis.

Bresch added, “Teva’s suit against the FDA was simply a desperate, last minute tactic, among others, to delay access to more affordable generic versions of Copaxone for patients in the US.”

Copaxone‘s US patents expire on May 24. Teva has appealed to the US Supreme Court over the expiry; the court will hear the case during its next session, which begins in October. Teva has sued the FDA for not yet deciding whether generic versions of Copaxone will require full clinical trials. It argues that there are substantive differences between brand Copaxone and generic versions of the drug, and has asked the FDA to require clinical trials, which could delay their entry to market by almost three years. The FDA has repeatedly declined to decide on the matter, although it has hinted that it will reject Teva’s request.

Published by Globes [online], Israel business news – www.globes-online.com 

–

In this article:, , ,

Newsletter



Advertisement

You May Also Like

World News

Good News From Israel

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...

November 15, 2015

Life-Style Health

Why search Dr. Google when you can hire a Real Personal Health Researcher?

Medint’s medical researchers provide data-driven insights to help patients make decisions; It is affordable- hundreds rather than thousands of dollars

February 4, 2018
Natalie Portman-From Movie Leon Natalie Portman-From Movie Leon

Entertainment

Natalie Portman Regrets Being Made a Lolita and Sexualized as a Child

The Movie The Professional is what made Natalie Portman a Lolita.

December 9, 2020
U-Coral Beach, Eilat HOTEL U-Coral Beach, Eilat HOTEL

Travel

Rating Israeli hotels

After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

January 1, 2013